Oxford BioMedica plc (LON:OXB) issued its quarterly earnings results on Monday. The biopharmaceutical company reported $0.00 earnings per share for the quarter, Yahoo Finance Previews reports. Oxford BioMedica plc had a negative net margin of 21.31% and a negative return on equity of 56.98%.
Oxford BioMedica plc (LON:OXB) opened at 8.70 on Monday. Oxford BioMedica plc has a 1-year low of GBX 2.98 and a 1-year high of GBX 11.25. The stock’s market capitalization is GBX 268.68 million. The firm has a 50-day moving average of GBX 8.91 and a 200-day moving average of GBX 6.42.
A number of research analysts recently weighed in on OXB shares. N+1 Singer raised their price target on shares of Oxford BioMedica plc from GBX 8.70 ($0.11) to GBX 10.20 ($0.13) and gave the company a “hold” rating in a research note on Thursday, August 31st. Jefferies Group LLC reaffirmed a “buy” rating and issued a GBX 13 ($0.17) price target on shares of Oxford BioMedica plc in a research note on Thursday, July 13th. Finally, Shore Capital reaffirmed a “not rated” rating on shares of Oxford BioMedica plc in a research note on Thursday, July 13th.
COPYRIGHT VIOLATION WARNING: This piece of content was reported by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.themarketsdaily.com/2017/09/11/oxford-biomedica-plc-oxb-releases-earnings-results.html.
In other Oxford BioMedica plc news, insider Peter Nolan bought 249,687 shares of Oxford BioMedica plc stock in a transaction on Monday, July 17th. The stock was purchased at an average cost of GBX 8 ($0.10) per share, for a total transaction of £19,974.96 ($25,797.44). Also, insider Martin Diggle sold 2,377,600 shares of Oxford BioMedica plc stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of GBX 10 ($0.13), for a total transaction of £237,760 ($307,064.45). Insiders acquired 1,278,720 shares of company stock valued at $11,062,661 over the last quarter.
Oxford BioMedica plc Company Profile
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.
Receive News & Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related companies with MarketBeat.com's FREE daily email newsletter.